Mirum Pharmaceuticals has grown revenue primarily through commercializing orphan drugs targeting cholestatic liver diseases and rare genetic disorders, enhanced by strategic acquisitions such as the Bile Acid Portfolio. Despite top-line growth, the company continues to report net losses driven by high operating expenses associated with sales expansion, R&D, and legal proceedings over patent protections. Mirum’s future growth hinges on advancing late-stage candidates like brelovitug and volixibat and expanding geographic reach while navigating complex regulatory and pricing environments. Robust operating cash flow improvement underpins operational resilience, but ongoing reliance on third-party manufacturers and the limited patient populations of its rare disease indications remain key constraints.